Interestingly, a recent published study successfully applied a major part of our novel idea in vivo by engineering CAR T cells with GLUT1 overexpression, leading to the increased metabolic fitness of primary T cells, reduced T-cell exhaustion, and enhanced anti-tumor efficacy against multiple different cancers in humanized murine models [83]. Here, SLC2A1 is linked to neoplasm.